Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where J. Moro is active.

Publication


Featured researches published by J. Moro.


Transplantation Proceedings | 2008

Tolerance Profile of the Proliferation Signal Inhibitors Everolimus and Sirolimus in Heart Transplantation

J. Moro; Luis Almenar; Luis Martínez-Dolz; I. Sánchez-Lázaro; J. Agüero; A. Salvador

INTRODUCTION The side effects of proliferation signal inhibitors (PSIs) have been characterized as a class. However, it would be convenient to assess them according to the molecule. OBJECTIVE To assess prospectively the tolerance of PSIs among heart transplant (HT) patients. PATIENTS AND METHODS We studied 56 HT patients who sequentially received PSIs to either withdraw (77%) or reduce the dosage of a calcineurin inhibitor; 42 received everolimus (EVE) and 14 sirolimus (SRL). We analyzed the demographic variables, side effects, and need to withdraw the drug during a median follow-up period of 365 days. RESULTS No differences between groups were observed upon analysis of the clinical and demographic variables when the treatment was changed owing to renal dysfunction (67%) or tumor (32%). No difference between groups was observed over the follow-up period (P = .28). Infection was the most common side effect, 28.6%: EVE, 14.3% versus SRL, 71.4% (P < .0001). Edema occurred in 26.8% of patients: EVE, 14.3% versus SRL, 64.3% (P = .001); diarrhea in 5.4% of patients: EVE, 2.4% versus SRL, 14.3% (P = .15). Treatment was withdrawn in 23.2% of the patients due to intolerance: EVE, 11.9% versus SRL, 57.1% (P < .0001). EVE showed significantly better survival without edema or infections or used for drug withdrawal upon Kaplan-Meier analysis, (P = .01; P = .0005; P = .0097). Only SRL use was shown to be an independent predictor of side effects. CONCLUSION Edema and infections are the main problems caused by PSIs. EVE may display a better tolerance profile than SRL.


Transplantation Proceedings | 2007

mTOR inhibitors: do they help preserve renal function?

J. Moro; Luis Almenar; Luis Martínez-Dolz; J. Agüero; J. Rueda; M.A. Arnau; M.T. Izquierdo; O. Cano; I. Sánchez-Lázaro; A. Salvador


Transplantation Proceedings | 2005

Predictive factors for development of diabetes mellitus post-heart transplant

Luis Martínez-Dolz; L. Almenar; L. Martı́nez-Ortiz; M.A. Arnau; C. Chamorro; J. Moro; A Osa; J. Rueda; C. Garcı́a; M Palencia


Transplantation Proceedings | 2007

Impact of smoking on survival after heart transplantation.

I. Sánchez-Lázaro; L. Almenar; Luis Martínez-Dolz; J. Moro; V. Ortiz-Martínez; M.T. Izquierdo; O. Cano; J. Agüero; F. Buendía; A. Salvador


Transplantation Proceedings | 2007

Mortality After Heart Transplantation in Adults With Congenital Heart Disease: A Single-Center Experience

M.T. Izquierdo; L. Almenar; Luis Martínez-Dolz; J. Moro; J. Agüero; I. Sánchez-Lázaro; O. Cano; V. Ortiz; R. Sánchez; A. Salvador


Transplantation Proceedings | 2007

Analysis of the impact of donor gender on early mortality.

M.T. Izquierdo; L. Almenar; Luis Martínez-Dolz; J. Moro; J. Agüero; I. Sánchez-Lázaro; O. Cano; V. Ortiz; R. Sánchez; A. Salvador


Transplantation Proceedings | 2007

Course of Patients With Chronic Hepatitis C Virus Infection Undergoing Heart Transplantation

O. Cano; L. Almenar; Luis Martínez-Dolz; J. Moro; M.T. Izquierdo; J. Agüero; R. Sánchez; V. Ortiz; I. Sánchez; A. Salvador


Transplantation Proceedings | 2007

mTOR Inhibitors and Their Secondary Effects in Cardiac Trasplant Recipients: A Descriptive Study

J. Moro; L. Almenar; Luis Martínez-Dolz; M.T. Izquierdo; J. Rueda; M.A. Arnau; J. Agüero; I. Sánchez-Lázaro; V. Ortiz; A. Salvador


Transplantation Proceedings | 2007

Ezetimibe in Heart Transplantation: Initial Experience

J. Moro; L. Almenar; Luis Martínez-Dolz; M.T. Izquierdo; J. Agüero; I. Sánchez-Lázaro; V. Ortiz; A. Salvador


Transplantation Proceedings | 2006

Induction Therapy With Daclizumab in Heart Transplantation— How Many Doses?

V. Ortiz; L. Almenar; Luis Martínez-Dolz; E. Zorio; C. Chamorro; J. Moro; J. Agüero; J. Rueda; M.A. Arnau; A. Salvador

Collaboration


Dive into the J. Moro's collaboration.

Top Co-Authors

Avatar

Luis Martínez-Dolz

Instituto Politécnico Nacional

View shared research outputs
Top Co-Authors

Avatar

Luis Almenar

Instituto Politécnico Nacional

View shared research outputs
Researchain Logo
Decentralizing Knowledge